N/A N=45 Bilateral Dispensing Clinical Trial of Stenfilcon A Against Etafilcon A for Astigmatism
Astigmatism
Primary: Comfort — 88; 78; 85; 77 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=76 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1293 Compared With a Basal Insulin in Participants With Type 1 Diabetes (MK-1293-005)
Type 1 Diabetes Mellitus
Primary: Comparison of MK-1293 and EU-Approved Lantus Duration of Pharmacodynamic Action During a 30-Hour Euglycemic Clamp Study — 30; 30 Hours
N/A N=90 Evaluation of the CooperVision, Inc. Fanfilcon A and Enfilcon A Daily Wear Contact Lenses When Used for Frequent Replacement for up to One (1) Month of Daily Wear
Myopia
Primary: Epithelial Edema - Fanfilcon A Lens (Test) — 100.0; 100.0; 99.1; 100.0 percentage of eyes
Phase 3 N=111 Effect of Fluticasone Furoate Inhalation Powder on the Hypothalamic-pituitary-adrenocortical Axis of Children Aged 5-11 Years With Asthma
Asthma
Primary: Change From Baseline (Expressed as a Ratio) in 0-24 Hour Weighted Mean Serum Cortisol at the End of the Six Week Treatment Period (D 42) in Intention-to-treat (ITT)…
Phase 3 N=302 Achieving Cannabis Cessation-Evaluating N-Acetylcysteine Treatment
Cannabis Dependence
Primary: The Odds of Negative Urine Cannabinoid Tests During Treatment. — 25; 21; 30; 22 cannabis negative urine tests — p=0.985
Phase 4 N=284 Clinical Evaluation of Narrow Band Imaging Colonoscope
Colonic Neoplasms
Primary: Neoplasm Miss Rate — 12.6; 12.1 Miss rate percentage
Phase 2 N=471 Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
Asthma
Primary: Percentage of QGE031 Participants With Clinically Important Improvement of <= -0.5 in the Asthma Control Questionnaire 7 (ACQ-7) Score Compared to Placebo — 63.16…
Phase 2 N=75 Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 Diabetes
Type 2 Diabetes Mellitus
Primary: Adjusted Percent Change From Baseline in Glomerular Filtration Rate (GFR) at Week 12 (Modified Last Observation Carried Forward [MLOCF]) — -2.92; -10.76; -3.40 % Change…
Phase 2 N=27 Effects of Melatonin on Insomnia Symptoms in Older Adults
Sleep Initiation and Maintenance Disorders
Primary: Peak Melatonin Level — 405; 3999; 52 pg/ml — p=<0.001
Phase 3 N=117 Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia
Alopecia
Primary: Number of Participants With Adverse Events (AE) Related to Sexual Function in the Double-blind Treatment Period — 5; 9 Participants — p=0.27
N/A N=21 Brain Morphometry in OA Patients Treated With Duloxetine
Pain · Osteoarthritis
Primary: Brain Regional Gray Matter Density — 0.420; 0.425 Gray Matter Density: 0 to 1
N/A N=42 Evaluating a Novel Working Memory Training Program to Decrease Symptoms of PTSD
Posttraumatic Stress Disorder
Primary: Change in Clinician Administered PTSD Scale; Re-experiencing — 11.78; 15.69 units on a scale
N/A N=70 A Study to Assess Immunity to Specific Microbial Antigens in Healthy Smokers and Non-smokers and in Subjects With Stable COPD
Respiratory Disorders
Primary: Anti-protein D Antibody Concentrations — 79.5; 66.9; 61.7; 72.8 EU/mL
N/A N=233 The Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity(DH)
Dentin Sensitivity
Primary: Change From Baseline in Schiff Sensitivity Score on Day 3 — -1.40; -0.38 Score on a scale — p=<0.0001
Phase 2 N=68 AN2728 Topical Ointment to Treat Mild-to-Moderate Plaque-Type Psoriasis
Psoriasis
Primary: Percentage of Participants Who Achieved Success in Physician's Global Assessment (PGA) of Disease Severity at Day 84 — 17.4; 13.6 percentage of participants